Guillain–Barré syndrome (GBS) is the most common serious immune-mediated disease affecting the peripheral nervous system (PNS). GBS is an acute diffuse illness affecting nerve roots and peripheral nerves, and occasionally the cranial nerves, often ascending from the feet over hours to days to the arms and sometimes bulbar muscles, resulting in motor weakness, and relatively sparing sensory functions; most patients who survive the acute paralysis recover completely within months. The disease was first described by the French neurologist, Landry, in 1859 (Inset 9.1).
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(Pt 3):597–605.PubMedCrossRefGoogle Scholar
McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. Plasmapheresis and Guillain-Barre syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. Apr 1988;23(4):347–53.PubMedCrossRefGoogle Scholar
McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet. 1991;338(8767):593–7.PubMedCrossRefGoogle Scholar
van der Meche FG, Schmitz PI, Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med. 1992;326(17):1123–9.PubMedCrossRefGoogle Scholar
Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2006(1):CD002063.Google Scholar
Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. May 2008;131(Pt 5):1197–208.PubMedGoogle Scholar
Koski CL, Baumgarten M, Magder LS, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2009;277(1–2):1–8.PubMedCrossRefGoogle Scholar
Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2009(1):CD001797.Google Scholar
Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46(8):878–84.PubMedCrossRefGoogle Scholar
Yu RK, Usuki S, Ariga T. Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infect Immun. Dec 2006;74(12):6517–27.PubMedCrossRefGoogle Scholar
Ilyas AA, Gu Y, Dalakas MC, Quarles RH, Bhatt S. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol. Jan 2008;193(1–2):87–93.PubMedCrossRefGoogle Scholar
Logina I, Donaghy M. Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. Oct 1999;67(4):433–8.PubMedCrossRefGoogle Scholar